drugset / Trial / NCT06709612

Postsurgical Analgesia After Hernia Repair

NCT06709612

Phase 2 Withdrawn AmacaThera Inc.
RandomizedParallel-groupSingle-blindSupportive care

Summary

The study is designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of three ascending doses of AMT-143 to determine the appropriate dose of AMT-143 for the management of postsurgical pain following inguinal hernia repair.

Timeline

Start
2025-01-27
Primary completion
2026-03
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-143 Unknown 1 ml
Subject AMT-143 Unknown 2 ml
Subject AMT-143 Unknown 3 ml
Comparator Ropivacaine Other / unclassified 50 mg

Indications

No indication recorded.